Research of stored specimens from women who became infected with HIV during the FEM-PrEP study supports existing evidence that viral resistance to tenofivir/emtricitabine appears to be rare among persons using pre-exposure prophylaxis (PrEP). The data demonstrate that the risk of viral resistance occurrence is highest in undiagnosed HIV-infected individuals initiating PrEP. The risk of viral resistance can be minimized by ensuring that patients initiating PrEP do not have HIV and by counseling patients to adhere to the daily PrEP regimen.
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women
Written By
Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Van Damme L.
